Bifidobacterium animalis subsp. lactis HN019 and Reduced Hospitalization Rate

Doses used in studies

Time to effect

Median: 2.8 months · IQR 2.8 months–2.8 months · Range 2.8 months–2.8 months — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityReported
The probiotic-containing formulae were well-tolerated: there were no cases of diarrhoea or differences in stool frequency or characteristics, no differences in infant growth or temperament, and no treatment-related adverse events.
from: Comparison of two probiotics in follow-on formula: Bifidobacterium animalis subsp. lactis
diarrhoeaReported
there were no cases of diarrhoea
from: Comparison of two probiotics in follow-on formula: Bifidobacterium animalis subsp. lactis
hospitalisationReportedSerious adverse event
No infants required hospitalisation.
from: Comparison of two probiotics in follow-on formula: Bifidobacterium animalis subsp. lactis

1 of 1 paper

Comparison of two probiotics in follow-on formula: Bifidobacterium animalis subsp. lactis HN019 reduced upper respiratory tract infections in Chinese infants.